Abstract
In 1968-1969, previously untreated patients with ALL were given high dose combination chemotherapy (POMP). This included on days 1-5, i.v., prednisolone 1000 mg/m2; methotrexate (MTX) 7.5 mg/m2; 6-mercaptopurine (6MP) 125 mg/m2; and, on day 1, vincristine 2 mg/m2. Once remission was achieved POMP was given every 2 weeks. The doses of 6-MP and MTX were increased to maximally tolerated levels in all pts. After 6 months, bischloroethylnitrosourea (BCNU) was given for 3 days at 50 mg/ m2 and pts. were randomized to receive POMP monthly for 6 months or no further therapy. Complete remission was achieved in 61/66 pts. (91%). Median remission duration for all 61 pts. was 13 months; 48 pts. completed the initial 6 months of therapy without relapse; 24 were randomized to receive further POMP therapy and 24 to no further therapy. The further therapy group had a median remission of 20 months with 7 pts. still in initial remission. The no further therapy group had a median remission of 11 months with 2 still in initial remission. These differences are significant at the p <.05 level by the generalized Wilcoxon test. A comparable group of 35 pts. had an intermediate remission duration of 17 months. These data indicate that even with intensive therapy in the first 6 months, cure of leukemia will not be possible in the majority of pts. Prolonged therapy is required for improved remission duration.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leventhal, B., Henderson, E., Graw, R. et al. THE IMPORTANCE OF DURATION OF THERAPY IN ACUTE LYMPHATIC LEUKEMIA (ALL). Pediatr Res 8, 404 (1974). https://doi.org/10.1203/00006450-197404000-00386
Issue Date:
DOI: https://doi.org/10.1203/00006450-197404000-00386